“I have always been impressed by Celyad's cutting edge technology and ambition

to find novel therapies for people with cancer. I followed the Company for many years before joining, and even more so from the moment the Company was listed on Euronext in 2013 and then on Nasdaq in 2015. This double listing was unique in Wallonia and I always thought that working in such a dynamic financial environment would be very exciting. We, the Finance Team, are responsible for managing all the financial operations of the business, and also for providing complete regulated financial information to our shareholders and new potential investors.”

David Georges – Senior Director, Finance
Joined Celyad Oncology in 2019